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Adjuvant therapy is one of the major advances in the treatment of breast carcinoma patients – but do all patients need it? New
predictive markers, which are able to save breast carcinoma patients from the most toxic adjuvant therapies, are still needed. The
expression of matrix metalloproteinases (MMP-2) has been previously linked to invasiveness of carcinoma cells. In this study, we
explored the role of MMP-2 as a prognostic factor in breast carcinoma in a large series to be able to show the favourable effect of
MMP-2 negativity in poor prognosis subgroup of hormone receptor-negative patients. The MMP-2 immunoreactive protein was
evaluated from primary adenocarcinoma of the breast in 453 cases by using a specific monoclonal antibody in immunohistochemical
stainings. The MMP-2 protein found in breast carcinoma tumour cells was here shown to be associated with a shortened recurrence-
free survival or relative overall survival (P¼0.03). It was shown here that MMP-2 negativity is significantly linked to favourable
prognosis in patients considered to be at risk due to their hormone receptor negativity. In the patient group presenting with a
progesterone receptor-negative tumour, the survival rate of the MMP-2-positive cases was 58% while it was 95% in MMP-2-negative
cases after 10 years of follow-up (P¼0.005). The present data shows for the first time that MMP-2 negativity could serve as a marker
for favourable prognosis in breast carcinoma patients with a hormone receptor-negative tumour usually associated with high risk.
MMP-2 is also shown to correlate to shortened survival independent of major prognostic indicators in patients with primary breast
carcinoma.
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Breast carcinoma is the most frequent malignancy among women
in Finland as well as in other Western countries (Finnish Cancer
Registry, 1995; Parkin et al, 1997). It is a pathologically and
clinically heterogenous disease with variable prognosis. Breast
carcinomas are potentially highly malignant tumours due to their
capacity to invade locally and to metastasise. The traditional
prognostic factors of breast carcinoma include the size of the
primary tumour, axillary lymph node involvement, tumour grade,
oestrogen or progesterone receptor status of the primary tumour
and menopausal status of the patients.
Tumour invasion and metastasis are the major causes of
treatment failure or death for carcinoma patients. The role of
matrix metalloproteinases (MMPs) in tumour invasion and
metastasis as well as in tumour angiogenesis is important. Matrix
metalloproteinase-2 (MMP-2/gelatinase A/72-kDa type IV collage-
nase) is a member of zinc-dependent endopeptidases that degrade
matrix proteins, among other type IV collagens in basement
membranes (Liotta and Stetler-Stevenson, 1990; Liotta et al, 1998;
Curran and Murray, 1999). The expression of MMP-2 has been
strongly associated with the progression of malignancy of several
types of carcinoma (D’Errico et al, 1991; Levy et al, 1991;
Ellenrieder et al, 2000; Sakata et al, 2000; Giannelli et al, 2002). In
primary skin melanoma (Va ¨isa ¨nen et al, 1998), lung carcinoma
(Kodate et al, 1997), ovarian carcinoma (Davidson et al, 1999) and
brain neoplasms (Ja ¨a ¨linoja et al, 2000), the expression of the
immunoreactive protein for MMP-2 was associated with a poor
prognosis. In several studies, MMP-2 has been shown to be
expressed in breast carcinoma (Liotta and Stetler-Stevenson, 1990;
Monteagudo et al, 1990; D’Errico et al, 1991; Davies et al, 1993;
Tryggvason et al, 1993; Iwata et al, 1996; Garbett et al, 1999, 2000;
Jones et al, 1999) and it has been localised in breast carcinoma
cells using immunohistochemical methods (Daidone et al, 1991;
Ho ¨yhtya ¨ et al, 1994). In limited series, MMP-2 positivity is
associated with unfavourable prognosis in both premenopausal
and postmenopausal node-positive breast carcinoma patients
(Talvensaari-Mattila et al, 1998, 1999, 2001).
This study is aimed at defining the possible favourable effect of
the MMP-2 negativity in primary breast carcinoma in high-risk
patient groups while confirming the MMP-2 immunoreactive
protein as a prognostic factor also in node-negative breast
carcinoma.
MATERIALS AND METHODS
Breast tissue samples were from the primary tumours of 453
patients operated on during the years 1981–1995 in Northern
Finland. The formalin-fixed, paraffin-embedded blocks were
obtained from the files of the Departments of Pathology, Oulu Received 25 March 2003; revised 2 July 2003; accepted 8 July 2003
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Kokkola and Rovaniemi. The minimum follow-up time was 60
months (range 60–150 months).
Stage, tumour size and axillary node involvement of breast
carcinoma were determined according to the UICC TNM
classification (Hermanek and Sobin, 1992). The tumours were
classified according to the World Health Organization’s Interna-
tional Classification of Breast Tumors (Scarff and Torloni, 1986).
The ductal carcinomas were graded (I–III) by evaluating tubule
formation, nuclear pleomorphism and the mitotic rate according
to the criteria of Bloom and Richardson (1957).
The patients were 26–85 years of age, the median age being 52
years. Ductal infiltrating carcinoma was the most frequent
histological type. In this material, the number of the node-positive
cases is over-represented, 302 out of 453 patients, to increase the
power to test the effect of MMP-2 negativity in advanced breast
carcinoma. A small tumour sample taken during the operation was
used for routine steroid receptor assays. Both oestrogen and
progesterone receptor charcoal assays were performed in 334
cases. In all, 65 tumours were both oestrogen and progesterone
receptor negative. Mastectomy with axillary evacuation was the
primary treatment in most of the cases, one case remained
inoperable.
All patients without distant metastases and with histologically
positive axillary lymph nodes, regardless of the number of nodes
or size of the primary tumour, received postoperative radiotherapy
covering the axillary, supraclavicular and internal mammary
lymph nodes and the chest wall around the mastectomy scar.
Adjuvant antioestrogen therapy had been used in 138 cases, most
of them with a stage II or III disease, and adjuvant cyclopho-
sphamide–methotrexate–fluorouracil (CMF) chemotherapy in
104 cases or FEC (5-fluorouracil-epirubicin-cyclophosphamide)
in 96 cases. Patients with metastatic disease (M1) were operated
(except one) and local radiotherapy was given. Additionally, the
patients received antioestrogen therapy (10 patients) or che-
motherapy (two patients). Recurrences in patients with receptor-
positive tumour were treated primarily with hormonal therapy.
Immunohistochemical staining
The histologic material fixed in 10% formalin and embedded in
paraffin was cut into 4mm slides and they were incubated for 12h
at 371C, dewaxed in a histological clearing agent, Histo-Clear
(National Diagnostics, Atlanta, GA, USA), and hydrated. The
specimens were treated with 0.4% pepsin (Sigma, St Louis, MO,
USA) for 20min at 371C. The avidin–biotin–immunoperoxidase
technique was used according to Hsu et al, 1981. Mouse
monoclonal antibody (CA-4001; Diabor Ltd, Oulu, Finland) against
MMP-2 was used as a primary antibody. The antibody has been
previously shown to detect the latent (inactive), 70–72kDa form of
MMP-2. The specificity has been confirmed by a Western blot
analysis (Ho ¨yhtya ¨ et al, 1994). Endogenous peroxidase activity was
blocked by incubating the slides in 3% hydrogen peroxide in
absolute methanol for 15min, and nonspecific binding was
blocked with 10% goat serum for 15min.
The specimens were incubated for 60min at room temperature
in a humidity chamber, and immunohistological staining was
continued using a Histostain-bulk kit (Zymed, San Francisco, CA,
USA) according to the manufacturer’s instructions. Biotinylated
anti-mouse IgG served as a second antibody, and the peroxidase
was introduced using a streptavidin conjugate. The slides were
washed thoroughly with phosphate-buffered saline between each
stage in the procedure. The antibody reaction was visualised using
a fresh substrate solution containing an aminoethyl carbazole
substrate kit (AEC, Sigma). The sections were counterstained with
haematoxylin, dehydrated and mounted in glycerol–vinyl–alcohol
(GVA mount, Zymed). For the negative controls, the primary
antibody was replaced with mouse nonimmuno IgG. For the
positive controls, we used previously known MMP-2-positive
specimens of breast carcinoma.
Evaluation of the MMP-2 immunostaining
A section was considered negative or positive according to the
absence or presence of positive staining of the neoplastic cells. The
staining was scored as follows: no positive cells, less than 50% of
the neoplastic cells staining positive (MMP-2þ) and 450% of the
neoplastic cells positive (MMP-2þþ).
Immunostaining for MMP-2 was scored by three independent
observers. Only cases giving repeatable scores in immunostaining
were included in the data. The clinical data were collected and
analysed after the evaluation of the immunostaining scores for a
given case. The scoring of the immunoreaction and collecting the
clinical data were performed independently without knowledge of
each other.
Statistical analysis
The score for MMP-2 immunoreactivity was compared with other
prognostic variables by the w
2 method. P-values o0.05 were
considered statistically significant.
Survival was defined as the time elapsing from the primary
operation to the date of death due to breast carcinoma. The
recurrence-free survival (RFS) was determined as time in months
from the date of diagnosis to the date of local recurrence or
metastasis.
Survival rates were analysed by the Kaplan–Meier method
(Kaplan and Meier, 1958) for up to 10 years of the follow-up.
Differences between the subgroups were compared by means of a
log-rank test (Mantel, 1966) for up to 10 years. The effect of MMP-
2 positivity on survival was analysed in various subgroups
representing the major prognostic variables recognised in breast
carcinoma.
The multivariate analysis was tested with the Cox’s regression
model of survival time (Cox, 1972). BMDP statistical software
(University of California Press, Berkeley, CA, USA) was used
(Dixon et al, 1990).
RESULTS
In this study, intracytoplasmic staining of the protein for MMP-2
was found in 78% of the primary tumours of breast carcinoma,
50% displaying an extensive positivity (450% of the tumour cells
positive; MMP-2þþ). Negative staining (MMP-2) was found in
22% of the primary tumours of breast carcinoma. The immunor-
eactive protein in carcinoma cells localised to the cytoplasm
(Figure 1A, B). There was no correlation between the MMP-2
protein expression and stage, grade or hormone receptor status
(Table 1).
A statistically significant correlation between MMP-2 positivity
and overall survival was found in this study. The 10-year overall
survival was 72% in patients with an MMP-2 immunoreactive
protein positive (þ) and 64% in patients with an MMP-2
immunoreactive protein strongly positive (þþ) breast carcino-
ma, compared to 77% in the patient group with an MMP-2-
negative primary tumour, the 10-year RFS being 60, 56 and 64%,
respectively (Figure 2A, B).
In the node-negative patient group, all patients with MMP-2-
negative immunostaining were alive in the follow-up time of 10
years. In the patient group with a positive immunohistochemical
staining for MMP-2, the overall survival was 87% (P¼0.03,
Table 2).
Out of 334 breast carcinoma patients, 72 were negative for
oestrogen receptors and 96 for progesterone receptors. In these
patients, the MMP-2 positivity indicated a very unfavourable
MMP-2 in breast carcinoma
A Talvensaari-Mattila et al
1271
British Journal of Cancer (2003) 89(7), 1270–1275 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yprognosis. In all, 58% of the patients presenting with MMP-2-
positive and oestrogen (n¼59) or progesterone (n¼96) receptor-
negative primary tumour were alive after the 10 years of follow-up.
In contrast, 90% of the patients with an MMP-2-negative,
oestrogen receptor-negative (n¼12) tumour and 95% of those
with an MMP-2 negative, progesterone receptor-negative (n¼20)
tumour were alive at that time (Figure 3A, B). The Kaplan–Meier
analysis showed that the RFS was 90 or 80% in patients with an
MMP-2-negative, oestrogen receptor-negative or progesterone
receptor-negative primary tumour, respectively, while it was 56%
in the MMP-2-positive tumours in both oestrogen- or progesterone
receptor groups (P¼0.047, 0.023).
In grade 2 and 3, tumours MMP-2 positivity correlated
significantly with shortened overall survival (P¼0.04). The 10-
year RFS of the patients with MMP-2-negative primary tumour was
57%, whereas it was 48% in those patients with a tumour
displaying MMP-2 positivity (P¼0.05), the overall survival being
64% vs 59%, respectively.
A multivariate analysis was conducted to evaluate further
whether the correlation between MMP-2 positivity and shortened
survival could be related to the association of MMP-2 with other
prognostic factors. The results showed that MMP-2 positivity in
Figure 1 Cytoplasmic immunostaining of MMP-2 in primary breast
carcinoma. Immunostaining was performed as described in Materials and
Methods by using an anti-MMP-2 monoclonal antibody: (A) negative ( ),
(B) positive (þþ) case.
Table 1 Expression of MMP-2 immunoreactive protein in breast
carcinoma
MMP-2 positive
nn
All patients 453 354 (78%)
Age (years) 26–85
T1–2 404 318 (79%)
T3–4 49 36 (73%)
N0 152 123 (81%)
N1–2 301 231 (77%)
M0 439 341 (78%)
M1 14 13 (93%)
Histology
Ductal infiltrating
Grade I 39 28 (72%)
Grade II–III 302 240 (80%)
Oestrogen receptor
Positive 262 199 (76%)
Negative 72 61 (85%)
Unknown 119
Progesterone receptor
Positive 236 181 (77%)
Negative 99 79 (80%)
Unknown 118
Adjuvant treatment
No 187 154 (82%)
Yes 226 200 (88%)
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Figure 2 Survival analysis (Kaplan–Meier) of the breast carcinoma
patients according to the MMP-2 immunoreactivity of the primary tumour:
(A) overall survival, (B) RFS. MMP-2 negative ( ), MMP-2 positivity; weak
(þ), strong (þþ). Log-rank analysis of MMP-2 negative vs strong positive:
(A) P¼0.03, (B) P¼0.05.
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(Table 3). MMP-2 positivity appeared to increase the risk of death
1.8-fold during the first 10 years of follow-up.
DISCUSSION
The expression of MMP-2 immunoreactive protein has been
associated with invasive and metastatic tumours in previous in
vitro studies (Liotta et al, 1980; Garbisa et al, 1987; Nakajima et al,
1987; Bernhard et al, 1990). In this study, intracytoplasmic
expression of the protein for MMP-2 was found in 78% of the
primary tumours of breast carcinoma. The amount of positive
cases is in line with previously published data (Monteagudo et al,
1990; Daidone et al, 1991; Visscher et al, 1994; Talvensaari-Mattila
et al, 1998, 1999, 2001; Lee et al, 1996). This study constitutes the
largest material of breast carcinoma published showing the
prognostic value of MMP-2.
In this material consisting of 453 cases, the MMP-2 immunor-
eactive protein was able to predict a relapse during the 10 years of
the follow-up. The 10-year RFS was 60% in patients with a low-
grade (þ) and 56% in those with a strongly positive (þþ)
Table 2 Recurrence-free and overall survival of breast carcinoma
patients according to MMP-2 staining in different patient groups
MMP-2 immunoreaction
Recurrence-free survival Overall survival
  +/++   +/++
All patients 64 59 77 68***
T1–2 66 60 80 70**
Node negative 79 78 100 87****
Node positive 58 48***** 61 56*****
Oestrogen receptor
Negative 90 56***** 90 58*****
Positive 55 55 75 67**
Progesterone receptor
Negative 80 56** 95 58*
Positive 55 55 71 67
Grade II–III 57 48***** 64 59****
*P¼0.005, **P¼0.02, ***P¼0.03, ****P¼0.04, *****Po0.05. The surviving
fraction is given as % at 10 years in Kaplan–Meier analysis.
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Figure 3 Relative survival of the breast carcinoma patients according to
the MMP-2 immunoreactivity of the primary tumour in hormone receptor-
negative patient groups: (A) oestrogen receptor negative, (B) progester-
one receptor negative patient groups. Log-rank analysis of MMP-2 negative
vs positive. (A) P¼0.05, (B) P¼0.005.
Table 3 Cox’s regression model of survival time
n¼452 b s.e. P OR 95% Cl for b OR’s P-value
MMP-2 0.02
Negative 99 1.00
Positive 353 0.579 0.245 1.78 1.10–2.88 0.02
Age (years) 0.02
o55 266 1.00
455 186 0.445 0.183 1.56 1.09–2.23 0.02
Tumour 0.001
1–2 403 1.00
3–4 49 1.106 0.223 3.02 1.95–4.67 0.001
Nodes 0.001
0 152 1.00
1–2 300 1.375 0.285 3.95 2.26–6.91 0.001
Grade 0.01
I 39 1.00
II–III 302 1.923 0.715 6.84 1.68–27.8 0.01
b¼coefficient; s.e.¼standard error of the mean; OR¼odds ratio.
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tumour. Also, the 10-year overall survival rate was significantly
inferior among these patients. These differences are high enough
to be also clinically significant, and especially the differences
between   and þþ groups suggest that the MMP-2 immunor-
eactive protein is worthy of careful evaluation as a possible marker
for biologic aggressiveness in breast carcinoma patients. Further,
the previous studies have failed to show any statistically significant
differences in survival between the patients with MMP-2-negative
vs -positive primary tumours in node-negative patient group. Here
the patient group presenting an MMP-2-negative primary breast
carcinoma without a lymph node involvement enjoyed an excellent
prognosis for survival, 100% of the patients being alive after 10
years of follow-up (Table 2). No difference was, however, found in
the RFS suggesting that MMP-2 negativity may be associated with
better responses to treatment of the metastatic disease and/or show
progression of the disease.
The patients with an MMP-2-negative breast carcinoma form a
relatively large patient group when the incidence of breast
carcinoma is taken into consideration. It is possible that the lack
of MMP-2 could become an important factor in certain subgroups
of breast carcinoma when selecting the adjuvant therapy. A well-
known risk factor in breast carcinoma is hormone receptor
negativity. It is interesting that 90% of the patients with an
oestrogen receptor negative, MMP-2 negative or 95% of the
patients with a progesterone receptor negative, MMP-2 negative
primary tumour were alive after the 10 years of the follow-up
(Figure 3A, B). On the contrary, only 58% of patients displaying
MMP-2 positivity and oestrogen or progesterone receptor
negativity were alive at that time. These differences were
statistically highly significant, suggesting that these patient groups
might need more attention in further studies. The patient group is
small in percentages (about 4% of all breast carcinoma patients),
but interesting both biologically and clinically. The number of
those patients still exceeds the number of patients representing
many more uncommon carcinoma types. The regulation of MMP-2
by female sex hormones may be an yet unknown mechanism
which could explain this result. This conclusion indicates the need
for further studies to explore the value of this enzyme in clinical
decision-making.
In grade 2 and 3 tumours, MMP-2 correlated significantly with
shortened RFS and overall survival (Table 2). It is interesting to
note that, MMP-2 negativity in this patient group was a strong
marker for a favourable prognosis. Barozzi et al (2002) reported
that TGF-a, MMP-2 and IGF-II seem to be suitable candidates for a
selective panel of markers designed to provide significant
information with respect to the current pathologic staging system
for patients with colorectal carcinoma.
In conclusion, we show here in a relatively large breast
carcinoma patient group that MMP-2 immunoreactive protein is
an independent prognostic indicator that might prove valuable in
certain subgroups, such as patients with a receptor-negative breast
carcinoma. The present data shows for the first time that MMP-2
negativity could serve as a marker for distinctly favourable
prognosis in breast carcinoma patients. MMP-2 positivity is also
shown to correlate to poor survival in node-negative breast
carcinoma.
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